An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a phase 3 trial. Takeda has reported updated results from its ALTA-1L trial ...

Pfizer’s Xalkori is already approved to treat patients with ROS1 mutations (alongside its use in ALK+ patients), but Ignyta’s drug looks likely to be superior, thanks in part to its ability to ...

Targeted therapies that help treat cancers caused by the METex14 mutation include: capmatinib (Tabrecta) tepotinib (Tepmetko) crizotinib (Xalkori) At the moment, there are no FDA-approved ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...